EUCTR2006-004144-23-BE进行中（未招募）不适用
Clinical Trial Application for a Phase II study in patients with hormone receptor positive breast cancer with bortezomib (Velcade) in the reversal of endocrine resistance. - the HoBo Study
AZ St Augustinus, Wilrijk0 个研究点目标入组 14 人开始时间: 2007年3月7日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 14
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •1)Female adult (> 18 years) patients with metastatic breast cancer,
- •2)Postmenopausal status defined as either
- •a. > 55 years
- •b.bilateral ovariectomy
- •c.< 55 years with menopausal FSH levels
- •d.patients on LH-RH agonists in combination with either SERM or AI must continue the LHRH agonist,
- •3)ER and/or PgR + disease (at least 10% of nuclei in the initial are either ER or PgR positive) as defined in the participating institution,
- •4)Measurable disease by RECIST,
- •5)All patients should have been treated either in the adjuvant or metastatic setting with tamoxifen and an AI,
- •6)Radiologically documented disease progression of disease as defined by RECIST criteria after second line (if prior adjuvant endocrine treatment and relapse within 12 months of stopping this treatment, this can be considered a resistance to this agent) endocrine treatment for metastatic disease being either tamoxifen or any aromatase inhibitor (AI), with patients still considered to be suitable candidates for a third line endocrine treatment,
- •7)Superficial measurable lesions will be included as measurable, provided it is photographed,
- •8)Patients need to be on this endocrine treatment for at least three months in order to clearly document endocrine resistance and exclude as much as possible late responses,
- •9)Disease progression has to documented on consecutive radiological examinations or photographs (excluding ultrasound and PET),
- •10)Adequate bone marrow reserve WCC > 3.0x109/L, ANC > 1.5x109/L, PLTs> 100x109/L, Hb >10gr/dL,
- •11)Normal liver function defined by a bilirubin < 1.25 x ULN and transaminases < 3 x ULN,
- •12)Life expectancy > 6 months,
- •13) One line of chemotherapy for metastatic disease is allowed provided this was not the last treatment received prior to study entry,
- •14) No peripheral neuropathy > grade 1,
- •15) No other life-threatening disease,
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1)Non-measurable disease as sole disease sites as defined by RECIST,
- •2)More than one line of chemotherapy for metastatic disease,
- •3)Prior radiotherapy within two weeks prior to study entry,
- •4)Surgery within two weeks prior to study entry,
- •5)Other invasive cancer diagnosis within 5 years prior to study entry,
- •6)Severe cardiovascular disease including myocardial infarction within 6 months of enrollment, New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina, clinically significant pericardial disease, or cardiac amyloidosis,
- •7)Uncontrolled diabetes mellitus, (if receiving antidiabetic agents, subjects must be on a stable dose for at least 3 months before first dose of study drug,
- •8)Pregnant or breast feeding,
- •9)Neuropathy > or = grade II,
- •10)Has known or suspected hypersensitivity or intolerance to boron, mannitol, or heparin, if an indwelling catheter is used
- •11) Serious medical or psychiatric conditions that precludes participation in this study.
研究者
相似试验
进行中（未招募）
1 期
ABORL - A Phase II trial aiming to evaluate the clinical interest of ABEMACICLIB in patients with locally advanced/metastatic head and neck cancer harboring an homozygous deletion of CDKN2A, and/or an amplification of CCND1 and/or of CDK6 refractory to standards treatmentsPatients with locally advanced/metastatic head and neck cancer after failure of platinum and cetuximab or anti-EGFR-basedMedDRA version: 20.0Level: PTClassification code 10067821Term: Head and neck cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-004537-25-FRCentre Léon Bérard25
进行中（未招募）
1 期
Clinical trial of phase 1/2 to evaluate the feasibility, safety, tolerability and preliminary efficacy of the administration of FAB117-HC, a drug whose active ingredient is HC016, allogeneic adipose derived adult mesenchymal stem cells expanded and pulsed with H2O2, in patients with acute traumatic spinal cord injury.Patients with acute traumatic spinal cord injuryMedDRA version: 18.1Level: LLTClassification code 10043064Term: T7-T12 level spinal cord injury, unspecifiedSystem Organ Class: 100000004863MedDRA version: 18.1Level: LLTClassification code 10043046Term: T1-T6 level spinal cord injury, unspecifiedSystem Organ Class: 100000004863EUCTR2015-005717-80-ESFerrer Internacional S.A
进行中（未招募）
不适用
Clinical trial to evaluate the feasibility and safety of the intracerebral infusion of stem cells in patients with cerebral strokeEUCTR2011-001393-26-ESFundación para la Investigación Biomédica del Hospital Clínico San Carlos
招募中
2 期
An investigator-initiated clinical trial of TM5614 for SSc-ILDInterstitial lung disease associated with systemic sclerosisD012595JPRN-jRCT2021230022Asano Yoshihide50
进行中（未招募）
不适用
ocal treatment of bronchopleural fistula with adilts stem cellsEUCTR2012-000292-16-ESFundación para la Investigación Biomédica del Hospital Universitario La Paz (FIBHULP)